Galectin Therapeutics Announces Completion of Patient Recruitment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Cirrhosis
August 02, 2016 08:45 ET
|
Galectin Therapeutics
NORCROSS, Ga., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer,...